Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study

Journal of Neuro-Oncology

Volumn 99, Issue 2, 2010, Pages 261-272

  Ardon, Hilko ^a   Van Gool, Stefaan ^a   Lopes, Isabel Spencer ^a   Maes, Wim ^a   Sciot, Raf ^a   Wilms, Guido ^a   Demaerel, Philippe ^a   Bijttebier, Patricia ^a   Claes, Laurence ^a   Goffin, Jan ^a   Van Calenbergh, Frank ^a   De Vleeschouwer, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Brain tumors; Dendritic cell vaccination; Glioblastoma multiforme; Immunotherapy

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; TEMOZOLOMIDE;

ADULT; ARTICLE; BLOOD TOXICITY; BRAIN ISCHEMIA; CANCER IMMUNOTHERAPY; CANCER SURGERY; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DENDRITIC CELL; DRUG WITHDRAWAL; DYSPHAGIA; EPILEPSY; EPILEPTIC STATE; FATIGUE; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LEUKAPHERESIS; LYMPHOCYTOPENIA; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; OVERALL SURVIVAL; PILOT STUDY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEASIBILITY STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956061272     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0131-y     Document Type: Article

References (62)

1. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoom K Belanger AA Brandes C Marosi U Bogdahn, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Eng J Med 352 987 996 10.1056/NEJMoa043330
2. M Brada K Hoang-Xuan R Rampling PY Dietrich LY Dirix D Macdonald JJ Heimans BA Zonnenberg JM Bravo-Marques R Henriksson, et al. 2001 Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse Ann Oncol 12 259 266 10.1023/A:1008382516636 11300335
3. JL Finlay JM Boyett AJ Yates JH Wisoff JM Milstein JR Geyer SJ Bertolone P McGuire JM Cherlow M Tefft, et al. 1995 Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Children's Cancer Group J Clin Oncol 13 112 123 7799011
4. C Nieder AL Grosu M Molls 2000 A comparison of treatment results for recurrent malignant gliomas Cancer Treat Rev 26 397 409 10.1053/ctrv.2000.0191 11139371
5. Tamber MS, Rutka JT (2003) Pediatric supratentorial high-grade gliomas. Neurosurg Focus 14. http://www.medscape.com/viewarticle/449870
6. P Kleihues F Soylemezoglu B Schauble BW Scheithauer PC Burger 1995 Histopathology, classification, and grading of gliomas Glia 15 211 221 10.1002/glia.440150303 8586458
7. S Bao Q Wu RE McLendon Y Hao Q Shi AB Hjelmeland MW Dewhirst DD Bigner JN Rich 2006 Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 756 760 10.1038/nature05236 17051156
8. A Eramo L Ricci-Vitiani A Zeuner R Pallini F Lotti G Sette E Pilozzi LM Larocca C Peschle R De Maria 2006 Chemotherapy resistance of glioblastoma stem cells Cell Death Differ 13 1238 1241 10.1038/sj.cdd.4401872 16456578
9. G Liu X Yuan Z Zeng P Tunici H Ng IR Abdulkadir L Lu D Irvin KL Black JS Yu 2006 Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma Mol Cancer 5 67 10.1186/1476-4598-5-67 17140455
10. RO Weller B Engelhardt MJ Phillips 1996 Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways Brain Pathol 6 275 288 10.1111/j.1750-3639.1996.tb00855.x 8864284
11. B Bodey B Bodey Jr SE Siegel HE Kaiser 2000 Failure of cancer vaccines: the significant limitations of this approach to immunotherapy Anticancer Res 20 2665 2676 10953341
12. G Pawelec A Engel M Adibzadeh 1999 Prerequisites for the immunotherapy of cancer Cancer Immunol Immunother 48 214 217 10.1007/s002620050568 10431692
13. T Roszman L Elliott W Brooks 1991 Modulation of T-cell function by gliomas Immunol Today 12 370 374 10.1016/0167-5699(91)90068-5 1958290
14. S De Vleeschouwer M Arredouani M Ade P Cadot E Vermassen JL Ceuppens SW Van Gool 2005 Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells Cancer Immunol Immunother 54 372 382 10.1007/s00262-004-0615-8 15692847
15. S Yoshida K Morii M Watanabe T Saito K Yamamoto R Tanaka 2001 The generation of anti-tumoral cells using dendritic cells from the peripheral blood of patients with malignant brain tumors Cancer Immunol Immunother 50 321 327 10.1007/s002620100201 11570586
16. S De Vleeschouwer LI Spencer JL Ceuppens SW Van Gool 2007 Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells J Neurooncol 84 131 140 10.1007/s11060-007-9362-y 17361330
17. H Okada H Tahara MR Shurin J Attanucci KM Giezeman-Smits WK Fellows MT Lotze WH Chambers ME Bozik 1998 Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms Int J Cancer 78 196 201 10.1002/(SICI)1097-0215(19981005) 78:2<196::AID-IJC13>3.0.CO;2-9 9754652
18. P Siesjo E Visse HO Sjogren 1996 Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment J Immunother Emphas Tumor Immunol 19 334 345
19. W Maes GG Rosas B Verbinnen L Boon S De Vleeschouwer JL Ceuppens SW Van Gool 2009 DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma Neuro Oncol 11 529 542 10.1215/15228517-2009-004 19336528
20. W Maes C Deroose V Reumers O Krylyshkina R Gijsbers V Baekelandt J Ceuppens Z Debyser SW Van Gool 2009 In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma J Neurooncol 91 127 139 10.1007/s11060-008-9691-5 18787761
21. S De Vleeschouwer M Rapp RV Sorg HJ Steiger W Stummer S Van Gool M Sabel 2006 Dendritic cell vaccination in patients with malignant gliomas: current status and future directions Neurosurgery 59 988 999 17143233
22. S Van Gool W Maes H Ardon T Verschuere S Van Cauter S De Vleeschouwer 2009 Dendritic cell therapy of high-grade gliomas Brain Pathol 19 694 712 10.1111/j.1750-3639.2009.00316.x 19744041
23. S De Vleeschouwer S Fieuws S Rutkowski F Van Calenbergh J Van Loon J Goffin R Sciot G Wilms P Demaerel M Warmuth-Metz, et al. 2008 Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme Clin Cancer Res 14 3098 3104 10.1158/1078-0432.CCR-07- 4875 18483377
24. SC Jameson 2002 Maintaining the norm: T-cell homeostasis Nat Rev Immunol 2 547 556 12154374
25. J Kjaergaard LX Wang H Kuriyama S Shu GE Plautz 2005 Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines J Neurosurg 103 156 164 10.3171/jns.2005.103.1.0156 16121986
26. G Liu Y Akasaki HT Khong CJ Wheeler A Das KL Black JS Yu 2005 Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy Oncogene 24 5226 5234 10.1038/sj.onc.1208519 15897911
27. RJ North 1984 Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells Cancer Immunol Immunother 16 175 181 10.1007/BF00205425 6231095
28. RJ North 1986 Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells J Exp Med 164 1652 1666 10.1084/jem.164.5.1652 2945892
29. DL Porter CH June 2005 T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up! Bone Marrow Transplant 35 935 942 10.1038/sj.bmt.1704953 15806121
30. CJ Wheeler A Das G Liu JS Yu KL Black 2004 Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination Clin Cancer Res 10 5316 5326 10.1158/1078-0432.CCR-04-0497 15328167
31. MM Bradford 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 248 254 10.1016/0003-2697(76)90527-3 942051
32. S Rutkowski S De Vleeschouwer E Kaempgen JEA Wolff J Kuhl P Demaerel M Warmuth-Metz P Flamen F Van Calenbergh C Plets, et al. 2004 Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study Br J Cancer 91 1656 1662 15477864
33. J Banchereau AK Palucka M Dhodapkar S Burkeholder N Taquet A Rolland S Taquet S Coquery KM Wittkowski N Bhardwaj, et al. 2001 Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine Cancer Res 61 6451 6458 11522640
34. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull NJ Duez A Filiberti H Flechtner SB Fleishman JC de Haes, et al. 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365 376 10.1093/jnci/85.5.365 8433390
35. M Groenvold MC Klee MA Sprangers NK Aaronson 1997 Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement J Clin Epidemiol 50 441 450 10.1016/S0895-4356(96)00428-3 9179103
36. JE Wolff E Daumling A Dirksen A Dabrock M Hartmann H Jurgens 1996 [Munster Heidelberg Abilities Scale-a measuring instrument for global comparison of illness sequelae] Klin Padiatr 208 294 298 10.1055/s-2008-1046486 8992097
37. Karnofsky DA, Burchenal BJ (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191-205
38. LM Liau RM Prins SM Kiertscher SK Odesa TJ Kremen AJ Giovannone JW Lin DJ Chute PS Mischel TF Cloughesy MD Roth 2005 Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment Clin Cancer Res 11 5515 5525 10.1158/1078-0432.CCR-05-0464 16061868
39. S De Vleeschouwer F Van Calenbergh P Demaerel P Flamen S Rutkowski E Kaempgen JEA Wolff C Plets R Sciot SW Van Gool 2004 Transient local response and persistent tumor control of recurrent malignant glioma treated with combination therapy including dendritic cell therapy J Neurosurg Pediatr 100 492 497
40. T Kikuchi Y Akasaki M Irie S Homma T Abe T Ohno 2001 Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells Cancer Immunol Immunother 50 337 344 10.1007/s002620100205 11676393
41. T Kikuchi Y Akasaki T Abe T Fukuda H Saotome JL Ryan DW Kufe T Ohno 2004 Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12 J Immunother 27 452 459 10.1097/00002371- 200411000-00005 15534489
42. LM Liau KL Black NA Martin SN Sykes JM Bronstein L Jouben-Steele PS Mischel A Belldegrun TF Cloughesy 2000 Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides: case report Neurosurg Focus 9 e8 10.3171/foc.2000.9.6.9 16817691
43. CJ Wheeler KL Black G Liu H Ying JS Yu W Zhang PK Lee 2003 Thymic CD8(+) T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality J Immunol 171 4927 4933 14568975
44. R Yamanaka T Abe N Yajima N Tsuchiya J Homma T Kobayashi M Narita M Takahashi R Tanaka 2003 Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial Br J Cancer 89 1172 1179 10.1038/sj.bjc.6601268 14520441
45. R Yamanaka J Homma N Yajima N Tsuchiya M Sano T Kobayashi S Yoshida T Abe M Narita M Takahashi R Tanaka 2005 Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial Clin Cancer Res 11 4160 4167 10.1158/1078-0432.CCR-05-0120 15930352
46. JS Yu CJ Wheeler PM Zeltzer H Ying DN Finger PK Lee WH Yong F Incardona RC Thompson MS Riedinger, et al. 2001 Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration Cancer Res 61 842 847 11221866
47. JS Yu G Liu H Ying WH Yong KL Black CJ Wheeler 2004 Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma Cancer Res 64 4973 4979 10.1158/0008-5472.CAN- 03-3505 15256471
48. H Okada FS Lieberman KA Walter LD Lunsford DS Kondziolka GK Bejjani RL Hamilton A Torres-Trejo P Kalinski Q Cai, et al. 2007 Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas J Transl Med 5 67 10.1186/1479-5876-5-67 18093335
49. DG Walker R Laherty FH Tomlinson T Chuah C Schmidt 2008 Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy J Clin Neurosci 15 114 121 10.1016/j.jocn.2007.08.007 18083572
50. CJ Wheeler KL Black G Liu M Mazer XX Zhang S Pepkowitz D Goldfinger H Ng D Irvin JS Yu 2008 Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients Cancer Res 68 5955 5964 10.1158/0008-5472. CAN-07-5973 18632651
51. T Gorlia MJ van den Bent ME Hegi RO Mirimanoff M Weller JG Cairncross E Eisenhauer K Belanger AA Brandes A Allgeier D Lacombe R Stupp 2008 Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 Lancet Oncol 9 29 38 10.1016/S1470-2045(07)70384-4 18082451
52. JT Jordan W Sun SF Hussain G DeAngulo SS Prabhu AB Heimberger 2008 Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy Cancer Immunol Immunother 57 123 131 10.1007/s00262-007-0336-x 17522861
53. PE Fecci DA Mitchell JF Whitesides W Xie AH Friedman GE Archer JE Herndon DD Bigner G Dranoff JH Sampson 2006 Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma Cancer Res 66 3294 3302 10.1158/0008-5472.CAN-05-3773 16540683
54. B Petrini B Andersson O Strannegard J Wasserman H Blomgren U Glas 1992 Monocyte release and plasma levels of interleukin-6 in patients irradiated for cancer In Vivo 6 531 534 1457747
55. C Pasare R Medzhitov 2003 Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells Science 299 1033 1036 10.1126/science.1078231 12532024
56. Z Fehervari S Sakaguchi 2004 Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells Int Immunol 16 1769 1780 10.1093/intimm/dxh178 15520045
57. AJ Muller GC Prendergast 2005 Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 65 8065 8068 10.1158/0008-5472.CAN-05-2213 16166276
58. AK Nowak BW Robinson RA Lake 2003 Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Res 63 4490 4496 12907622
59. GV Masucci E Mansson-Brahme B Ragnarsson-Olding B Nilsson G Wagenius J Hansson 2006 Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma Melanoma Res 16 357 363 10.1097/01.cmr.0000205019.23612.a1 16845332
60. E Jouanneau D Poujol S Gulia I Le Mercier JY Blay MF Belin I Puisieux 2006 Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model Cancer Immunol Immunother 55 254 267 10.1007/s00262-005-0040-7 16133115
61. WJ Curran Jr CB Scott J Horton JS Nelson AS Weinstein AJ Fischbach CH Chang M Rotman SO Asbell RE Krisch DF Nelson 1993 Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 704 710 10.1093/jnci/85.9.704 8478956
62. RO Mirimanoff T Gorlia W Mason MJ van den Bent RD Kortmann B Fisher M Reni AA Brandes J Curschmann S Villa, et al. 2006 Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial J Clin Oncol 24 2563 2569 10.1200/JCO.2005.04.5963 16735709